-
Featured
YAP1 Oncogene Synergizes with HPV to Promote Cervical Cancer
Researchers have provided in vitro and in vivo evidence that the YAP1 oncogene can induce cervical cancer regardless of HPV infection. Further, the synergism between HPV and YAP1 significantly accelerates the development of cervical cancer and HPV vaccination remains vitally important.
-
Featured
Minimally Invasive Surgery Linked to Shorter Survival in Early-Stage Cervical Cancer
Among women with early-stage cervical cancer who undergo radical hysterectomy, survival after minimally invasive surgery is significantly shorter than after open surgery, according to the largest-ever investigation of this question.
-
Featured
Combination Immunotherapy May Be the Best Treatment for Certain Uterine Cancers
Mass General researchers evaluated patients with six uterine cancer subtypes to identify those with the most potential for immunotherapy treatment.
-
Review: Barriers to Cervical Cancer Prevention in Ukraine
Annekathryn Goodman, MD, gynecologic oncologist and co-director of Women's Global Health at Massachusetts General Hospital, and colleagues have documented a need for Ukraine to expand awareness of and access to cervical cancer screening and human papillomavirus vaccination programs.
-
Hospital-level Factors Affect Use of Sentinel Lymph Node Biopsy in Early Vulvar Cancer
Alexandra S. Bercow, MD, and colleagues found U.S. patients with early-stage vulvar cancer treated at minority-serving and low-volume hospitals are less likely to undergo sentinel lymph node biopsy. Use of the technique at minority-serving hospitals decreased 67% from 2012 to 2018 despite increasing nationwide.
-
Lymph Node Evaluation Underutilized for Early-stage Vulvar Cancer
Massachusetts General Hospital researchers found in a nationwide study that contrary to guidelines, 34% of eligible patients with early-stage vulvar cancer did not undergo lymph node evaluation. Among patients 80 and older, the figure was 49%, even though withholding lymph node assessment did not improve survival.
Mass General Cancer Center Contributors
-
Cheng Wang, PhD
Associate Investigator, Vincent Center for Reproductive Biology, Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
Recent Article
Cervical Cancer: Oncogene YAP1 Plays Central Role in Unconventional Carcinogenesis Mechanism
-
Eric L. Eisenhauer, MD
Chief, Division of Gynecologic Oncology, Massachusetts General Hospital
Recent Article
Lymph Node Evaluation Underutilized for Early-stage Vulvar Cancer -
Marcela G. del Carmen, MD
Chief Medical Officer, Massachusetts General Physicians Organization and Massachusetts General Hospital, Gynecologic Oncologist, Department of Obstetrics and Gynecology, Clinician, Center for Gynecologic Oncology, Mass General Cancer Center
Recent Article
Lymph Node Evaluation Underutilized for Early-stage Vulvar Cancer
-
Mary E. Sabatini, MD, PhD
Medical Director, Clinic for Reproductive Health and Cancer, Medical Director, Third Party Reproduction
Recent Article
The Müllerian Inhibiting Substance: Changing the Fertility Landscape for Young Women with Cancer
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
